Author Archives: admin


Stem cell discovery: Astrocytes could repair stroke brain damage

Featured Article Academic Journal Main Category: Stroke Also Included In: Neurology / Neuroscience;Stem Cell Research Article Date: 29 Jul 2013 - 0:00 PDT

Current ratings for: Stem cell discovery: Astrocytes could repair stroke brain damage

4.5 (6 votes)

Stem cell researchers have discovered that astrocytes may prove useful against stroke and other brain disorders.

Astrocytes - neural cells that form the blood-brain barrier and so control what can and cannot enter the brain from the blood supply - have previously been overlooked in this area of stroke research.

A collaborative study published in Nature Communications suggests that astrocytes can do far more than simply support nerve cells (neurons).

Wenbin Deng, senior author of the study and associate professor of biochemistry and molecular medicine at UC Davis in California, told Medical News Today:

"This exciting research uncovers the brain-protective powers of stem cell-derived astrocytes.

Astrocytes may help to limit the spread of damage after an ischemic brain stroke in patients, and may also help to regenerate and repair damaged brain cells.

Both of these actions may lead to better functional recovery in patients."

Read this article:
Stem cell discovery: Astrocytes could repair stroke brain damage

De Leon: Medical Tourism and the Future of Stem Cell Therapy (Part 3)

THE International Society for Stem Cell Research (ISSCR), an independent, non-profit organization has been established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell research and application. Members are admitted on the basis of their professional credentials as scientists or clinicians working in the field of stem cell research. Over the years, ISSCR has raised its concerns regarding stem cell therapies that are being offered worldwide before being scientifically and clinically proven safe and effective. The Catholic Church, supports stem cell research, with an introduction for a book on the subject by no less than now Pope Emeritus Benedict XVI.

Associated press has reported that Benedict XVI wrote the introduction for "The Healing Cell: How the Greatest Revolution in Medical History Is Changing Your Life" co-authored by Dr. Robin Smith, Msgr. Tomasz Trafny, and Max Gomez. The Catholic Church supports using adult stem cells in scientific research, especially when it will benefit society. However, The Church has consistently opposed research on embryonic stem cells.

Stem cell therapies are just about all new and experimental. ISSCR contends that most medical discoveries are based on years of research performed at universities and companies, requiring a long process that shows first in laboratory studies and then in clinical research that something is safe and will work. Like a new drug, stem cell therapies must be assessed and meet certain standards before receiving approval from national regulatory bodies to be used to treat people. The range of diseases where stem cell treatments have been shown to be beneficial in responsibly conducted clinical trials is still extremely limited. The best defined and most extensively used is blood stem cell transplantation to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers. Some bone, skin and corneal diseases or injuries can be treated with grafting of tissue that depends upon stem cells from these organs. These therapies are also generally accepted as safe and effective by the medical community. The ISSCR is cautioning the public to be wary of clinics that offer treatments with stem cells that originate from a part of the body that is different from the part being treated. Snake oil salesmen associated with those clinics are preying on the hopes of desperate patients/potential victims trying to make people believe that such treatment are effective in curing diseases in the absence of strong scientific evidence. If your doctor does not have a compelling reason to believe that your disease can be treated effectively with a therapy that is being offered and is not supported by a compelling evidence in scientific literature and that it hasnt been the basis of sound clinical trials is not open to the light of day and replicated in independent clinics -- then there is reason to be skeptical of these potential therapies and that you should be very cautious in engaging these clinics.

There has been enormous amount of excitement that stem cell treatments offer. It is important to realize that those opportunities are in the future. There are no established and proven stem cell treatments that work yet for some of the incurable diseases today (e.g. spinal injury, or Alzheimers); what works today that we can be sure about is bone transplantation. Therapies based on stem cells are still new and there is a so much that has yet to be discovered and tapped. Furthermore, side effects and long-term safety must be determined, since transplanted cells may remain for many years in patients bodies. Therefore, careful monitoring and extended follow-up of patients who receive stem cell treatments is extremely important. Patients intending to undergo stem cell treatment need to be sure that there is good scientific evidence that the treatment is safe and effective, and that your rights as a patient are being respected. Ask for evidential support pertaining to pre-clinical studies that have been published and reviewed by other experts in the field, and is approved by the Bureau of Food and Drugs administration. Other warning signs offered by ISSCR (www.isscr.org) that each patient should be cautious about include:

1. Claims based on patient testimonials. Patients want to believe so much that a treatment is helping them that they can convince themselves that it has. (Placebo effect) They may even have experienced some recovery unrelated to the treatment. Unless there has been carefully evaluated clinical research it is very difficult to know what is a true effect of the treatment and what you can expect.

2. Multiple diseases treated with the same cells. Unless the diseases are related, such as all being diseases of the blood, different diseases, such as Parkinsons disease and heart disease, would be expected to have very different treatments. Also, you want to be treated by a doctor that is a specialist in your disease.

3. The source of the cells or how the treatment will be done is not clearly documented.

This should be clearly explained to you in a treatment consent form. In addition, there should be a protocol that outlines the treatment in detail to the medical practitioner. The protocol is the operating manual for the procedure. While it may not be made available to you automatically, you should be able to request this. For a clinical trial or experimental treatment, protocols should have been reviewed for scientific merit by independent experts and approved by an ethics committee to ensure that the rights and well-being of the participants will be respected. Ask who has approved this protocol and when the approval expires.

4. Claims there is no risk. There is always risk involved with treatment. Information about the possible risks should be available from preclinical or earlier clinical research.

5. High cost of treatment or hidden costs. It is not customary for someone to pay to be in a clinical trial (other than perhaps travel and other personal expenses). Consider whether you should pay for a treatment that is unproven. Furthermore, ask about the costs of emergency medical care if something goes wrong, particularly if you are outside your own country.

See original here:
De Leon: Medical Tourism and the Future of Stem Cell Therapy (Part 3)

BrainStorm's NurOwn Cell Therapy Receives Orphan Drug Designation in the European Union for ALS

NEW YORK, NY and PETAH TIKVA, ISRAEL--(Marketwired - Jul 29, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Commission has granted Orphan Drug Designation for NurOwn, the Company's stem cell therapy consisting of autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors, for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease.NurOwn received Orphan Drug Designation from the Food and Drug Administration (FDA) in 2011.

Orphan drugs benefit from 10 years market exclusivity in the European Union (EU) after marketing approval. Additional benefits for sponsor companies include reduced fees for various centralized activities including applications for marketing authorization, inspections and protocol assistance, as well as possible eligibility for EU grants and other R&D-supporting initiatives.

BrainStorm is currently conducting a Phase IIa dose-escalating trial with 12 ALS patients at the Hadassah Medical Center in Jerusalem, Israel. The company anticipates launching a Phase II multi-center trial at three leading institutions in the United States towards the end of 2013, pending FDA approval.

About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

More:
BrainStorm's NurOwn Cell Therapy Receives Orphan Drug Designation in the European Union for ALS

Bank on it? A $60,000 bet on stem-cell cures

Forget about cash-start banking your body.

Using a technology that echoes science fiction movies, a French company is offering people a "bank" to store their own stem cells for years in a bet that those cells may be used to grow replacement organs and possibly save their lives someday.

"It's a personal deposit of your cell," said Dr. Andr Choulika, CEO of the biotech company Cellectis, which is launching the stem-cell bank known as Scil this month.

Given the rate of developments in stem-cell research and their potential for curbing health costs, Choulika thinks Scil's model of creating and storing stem cells one day will become so cheap that it will become mandatory for people with medical insurance.

"This pace of science currently goes so fast, probably in a few years, less than 10 years, everyone will have their own cell backup, and it will be a requirement," said Choulika, whose company is named after the Gaelic word for "story," and is pronounced "sail" by Choulika.

"We believe that regenerative medicine is the future," he said.

In the present, though, it is anything but cheap. Scil's services cost $60,000, Choulika said, adding that it is "a one-time payment, for your life."

(Read more: Hot biotech IPOs )

Choulika said he expects enthusiastic adoption by wealthy clients, as has been seen with other new technologies. Then, system improvements and competition could drive the initial price down considerably.

"It's expensive, or it seems expensive, for one reason," Choulika said. "We don't know how many people are going to sign up, and it's a very complex and sophisticated technology," he said. The number of people now who could both afford the process and be interested in trying it might top 1 million.

Excerpt from:
Bank on it? A $60,000 bet on stem-cell cures

Big bet on future stem-cell cures

Forget about cashstart banking your body.

Using a technology that echoes science fiction movies, a French company is offering people a "bank" to store their own stem cells for years in a bet that those cells may be used to grow replacement organs and possibly save their lives someday.

"It's a personal deposit of your cell," said Dr. Andr Choulika, CEO of the biotech company Cellectis, which is launching the stem-cell bank known as Scil this month.

Given the rate of developments in stem-cell research and their potential for curbing health costs, Choulika thinks Scil's model of creating and storing stem cells one day will become so cheap that it will become mandatory for people with medical insurance.

"This pace of science currently goes so fast, probably in a few years, less than 10 years, everyone will have their own cell backup, and it will be a requirement," said Choulika, whose company is named after the Gaelic word for "story," and is pronounced "sail" by Choulika.

"We believe that regenerative medicine is the future," he said.

In the present, though, it is anything but cheap. Scil's services cost $60,000, Choulika said, adding that it is "a one-time payment, for your life."

(Read more: Hot biotech IPOs)

Choulika said he expects enthusiastic adoption by wealthy clients, as has been seen with other new technologies. Then, system improvements and competition could drive the initial price down considerably.

"It's expensive, or it seems expensive, for one reason," Choulika said. "We don't know how many people are going to sign up, and it's a very complex and sophisticated technology," he said. The number of people now who could both afford the process and be interested in trying it might top 1 million.

View post:
Big bet on future stem-cell cures

California agency adopts $70M plan for stem cell clinical trial network

The governing board of the California Institute for Regenerative Medicine voted Thursday to adopt a $70-million plan to develop a network of clinics for conducting trials of experimental stem-cell therapies.

The vote authorizes CIRM to begin accepting applications from academic institutions interested in hosting clinics. Ultimately, the Alpha Stem Cell Clinics Network will include up to five clinics as well as a coordinating center to shoulder some of their load, such as enrolling patients and handling the paperwork involved in clinical trials.

The board approved the plan by a vote of 19 to 1, according to David Jensen, publisher of the California Stem Cell Report. The one dissenter was Joan Samuelson, founder of the Parkinson's Action Network, "who questioned whether the plan was premature and whether existing scientific research justified development of the clinics," Jensen reported.

The Alpha network reflects CIRM's recent focus on helping researchers convert stem-cell discoveries from the lab into useful treatments for patients with a range of conditions, including Parkinson's, Type 1 diabetes and spinal cord injuries.

Scientists value stem cells because they are capable of growing into a variety of cell types in the body. That means that -- under the right conditions -- they could be used to make cells that would replace the myelin that is lost in patients with multiple sclerosis, disrupting communication in the nervous system and causing symptoms like muscle spasms and and speaking problems. In principle, stem cells could also be coaxed to grow into a primitive liver that, when transplanted into a patient, would mature on its own.

"If we went 10 years and had no clinical treatments, it would be a failure," CIRM's director, Alan Trounson, explained in 2010. "We need to demonstrate that we are starting a whole new medical revolution."

The state agency was created by Proposition 71, the 2004 ballot measure that earmarked $3 billion for stem cell research. The initial motivation was to bankroll research on human embryonic stem cells after President George W. Bush set strict limits on the use of federal funds for such work.

That focus broadened after President Obama relaxed those limits. The development of induced pluripotent stem cells -- which behave very much like embryonic stem cells but are not made from embryos and therefore could qualify for federal funding -- also reduced the need for CIRM to fund basic research.

In its plan for establishing the Alpha network, CIRM officials appear to anticipate the day when the agency's $3 billion in funding runs out. (That could happen as soon as 2017, unless another ballot initiative brings more money or some other funding source materializes.) Institutions applying for one of the five slots will have to convince CIRM that they'll sustain their clinic "over the long term, when CIRM may no longer be around," my colleague Eryn Brown reported.

Another reason to create the clinical trial network is to make it easier for patients to find reliable information about stem cell research and therapies, CIRM officials said.

More here:
California agency adopts $70M plan for stem cell clinical trial network

Christiano fights for life after operation

WA Derby winner Alta Christiano is fighting for his life after suffering an adverse reaction to stem-cell treatment.

The Gary Hall Sr-trained star has been closely monitored at the Lark Hill Veterinary Clinic since the procedure two weeks ago.

Connections opted for the treatment to repair Alta Christiano's near fore suspensory ligament, which he tore after a Byford trial win in May.

The three-year-old is unbeaten from three starts in WA after a syndicate of Hall's clients bought an 80 per cent share in him from New Zealand owners.

He scored a brilliant win over Macha in the $200,000 WA Derby (2536m) at Gloucester Park in April.

"We don't know if he'll pull through, but we're hoping," Hall said.

"He's still under constant treatment. We're not sure if he picked up an infection or had a bad reaction to the stem-cell treatment."

Hall is hoping for a change of fortune at Gloucester Park tonight.

He has Real Hammer and Heez Orl Black taking on smart three-year-old Condrieu in the feature race, the $35,000 John Higgins Memorial (2130m).

The Greg and Skye Bond-trained Condrieu, a winner of three of his past five starts, is the one to beat from barrier three.

Read the original:
Christiano fights for life after operation

Epilepsy in a Dish

Stem cell research reveals clues to disease's origins and possible treatment.

Epilepsy in a dish: Stem cell research reveals clues to disease's origins and possible treatment

U-M-led study of neurons created from skin of patients with Dravet syndrome

A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.

The findings, reported by a team of scientists from the University of Michigan Medical School and colleagues, use a technique that could be called "epilepsy in a dish".

By turning skin cells of epilepsy patients into stem cells, and then turning those stem cells into neurons, or brain nerve cells, the team created a miniature testing ground for epilepsy. They could even measure the signals that the cells were sending to one another, through tiny portals called sodium channels.

In neurons derived from the cells of children who have a severe, rare genetic form of epilepsy called Dravet syndrome, the researchers report abnormally high levels of sodium current activity. They saw spontaneous bursts of communication and "hyperexcitability" that could potentially set off seizures. Neurons made from the skin cells of people without epilepsy showed none of this abnormal activity.

They report their results online in the Annals of Neurology, and have further work in progress to create induced pluripotent stem cell lines from the cells of patients with other genetic forms of epilepsy. The work is funded by the National Institutes of Health, the American Epilepsy Society, the Epilepsy Foundation and U-M.

The new findings differs from what other scientists have seen in mice -- demonstrating the importance of studying cells made from human epilepsy patients. Because the cells came from patients, they contained the hallmark seen in most patients with Dravet syndrome: a new mutation in SCN1A, the gene that encodes the crucial sodium channel protein called Nav1.1. That mutation reduces the number of channels to half the normal number in patients' brains.

"With this technique, we can study cells that closely resemble the patient's own brain cells, without doing a brain biopsy," says senior author and team leader Jack M. Parent, M.D., professor of neurology at U-M and a researcher at the VA Ann Arbor Healthcare System. "It appears that the cells are overcompensating for the loss of channels due to the mutation. These patient-specific induced neurons hold great promise for modeling seizure disorders, and potentially screening medications."

Read more here:
Epilepsy in a Dish

California Stem Cell Submits FDA Phase III Clinical Trial Protocol for the Treatment of Metastatic Melanoma

IRVINE, Calif.--(BUSINESS WIRE)--

California Stem Cell, Inc. (CSC) announced today the submission of a Phase III protocol to the U.S. Food and Drug Administration (FDA) for a randomized, double-blind study in metastatic melanoma. The multicenter trial will examine the effectiveness of CSCs patient specific cancer immunotherapy in patients with recurrent stage III or stage IV metastatic melanoma.

The study, led by Chief Medical Officer Robert Dillman, M.D., will explore the efficacy of subcutaneous injections of autologous dendritic cells that have been loaded with irradiated autologous tumor cells suspended in GM-CSF (DC-TC). The protocol calls for approximately 250 adult patients to be randomized in a 2:1 ratio to receive either the DC-TC or a control treatment. Doses will be administered weekly for three consecutive weeks, then monthly for the following five months. The primary and sole efficacy endpoint will be overall survival.

CSCs submission of the Phase III protocol comes on the heels of two earlier Phase II clinical studies in which the combined median 5-year survival in patients with stage IV melanoma was a remarkably high 51%.

This therapy has been proven to be safe and appears to prolong survival in late stage melanoma. We are very excited to be advancing this program into Phase III trials, so that we can further evaluate what we believe to be a very promising option for cancer patients, said Robert Dillman, M.D., Chief Medical Officer at CSC.

About California Stem Cell

California Stem Cell Inc. (CSC) is an Irvine, CA-based company focused on the development of stem cell-based therapies for metastatic cancers, spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS, or Lou Gehrigs Disease).

CSC has proprietary methods to generate human stem cell lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes.

Follow us on Twitter: http://twitter.com/castemcell

See original here:
California Stem Cell Submits FDA Phase III Clinical Trial Protocol for the Treatment of Metastatic Melanoma